Lamotrigine-13C3,d3 (CAS 1246815-13-3)

Lamotrigine-13C3,d3 is an isotopically and deuterium labeled form of Lamotrigine (sc-201079). Lamotrigine functions as an inhibitor of voltage gated sodium channels of presynaptic neurons. Studies indicate that Lamotrigine blocked sustained repetitive firing of neurons in a dose dependent manner in cultured mouse spinal cords. These studies indicate that Lamotrigine is effective at suppressing the release of glutamate and aspartate, but have no effect on acetylcholine and GABA release. Lamotrigine is inactivated by liver microsomes, via hepatic glucuronidation. It is believed that Lamotrigine modulates the fast voltage-dependent sodium currents in a manner similar to phenytoin and carbamazepine (sc-202518). Furthermore, Lamotrigine displays a small frequency dependent inhibition of depolarized potentials that result from sodium currents. Lamotrigine-13C3,d3 can be beneficial in research due to its various labels, which makes mechanistic determination of reactions easier in situ.

Lamotrigine-13C3,d3 (CAS 1246815-13-3) References

1. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro.  |  Cunningham, MO. and Jones, RS. 2000. Neuropharmacology. 39: 2139-46. PMID: 10963757
2. A novel drug binding site on voltage-gated sodium channels in rat brain.  |  Riddall, DR., et al. 2006. Mol Pharmacol. 69: 278-87. PMID: 16219909
3. Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders.  |  Malik, S., et al. 2006. Expert Rev Neurother. 6: 1609-27. PMID: 17144777
4. Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice.  |  Lagrue, E., et al. 2007. Pediatr Res. 62: 14-9. PMID: 17515828
5. Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy.  |  Papazisis, G., et al. 2008. Int J Neuropsychopharmacol. 11: 321-9. PMID: 17897482
6. [Optimisation of a high-efficiency liquid chromatography technique for measuring lamotrigine in human plasma].  |  Rivas, N., et al. 2010. Farm Hosp. 34: 85-9. PMID: 20304367
7. Quantification of lamotrigine in patient plasma using a fast liquid chromatography-tandem mass spectrometry method with backflush technology.  |  Wong, JM., et al. 2015. Ther Drug Monit. 37: 188-97. PMID: 25162213
8. A simple, rapid and stability indicating validated method for quantification of lamotrigine in human plasma and dry plasma spot using LC-ESI-MS/MS: Application in clinical study.  |  Namdev, KK., et al. 2018. J Chromatogr B Analyt Technol Biomed Life Sci. 1072: 362-369. PMID: 29223050
9. Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.  |  Ambrus, R., et al. 2020. Molecules. 25: PMID: 32120992
10. Preparation and characterization of lamotrigine containing nanocapsules for nasal administration.  |  Gieszinger, P., et al. 2020. Eur J Pharm Biopharm. 153: 177-186. PMID: 32531424
11. Acute effects of lamotrigine (BW430C) in persons with epilepsy.  |  Binnie, CD., et al. 1986. Epilepsia. 27: 248-54. PMID: 3698937
12. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats.  |  Miller, AA., et al. 1986. Epilepsia. 27: 483-9. PMID: 3757935
13. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action.  |  Leach, MJ., et al. 1986. Epilepsia. 27: 490-7. PMID: 3757936
14. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam.  |  Cohen, AF., et al. 1985. Br J Clin Pharmacol. 20: 619-29. PMID: 4091994